| Ong, Tiong |
NCT05687591: Left Atrial Appendage Occlusion With The Amplatzer Amulet Device: The Southeast Asia Observational Study |
|
|
| Recruiting | N/A | 100 | RoW | Amplatzer Amulet Left Atrial Appendage Occlusion Device | Sarawak Heart Centre, InnoSignum, Abbott | Atrial Fibrillation | 10/24 | 10/24 | | |
REVERSE, NCT05846893: Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease |
|
|
| Recruiting | N/A | 1436 | RoW | SeQuent® Please NEO drug-coated balloon catheter, Current-generation drug-eluting stent | B. Braun Medical Industries Sdn. Bhd., B. Braun Melsungen AG, Ulsan University Hospital, European Cardiovascular Research Center, Seoul National University Hospital, Universität des Saarlandes | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Coronary Stenosis, De Novo Stenosis | 10/26 | 09/28 | | |
| Chen, Jen-Shi |
| Active, not recruiting | 2 | 34 | RoW | CVM-1118, TRX-818 | TaiRx, Inc. | Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma | 09/24 | 12/25 | | |
NCT05048901: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors |
|
|
| Recruiting | 1/2 | 49 | RoW | Cabozantinib, Cabometyx, Lanreotide, Somatuline | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Neuroendocrine Tumors,Gastroenteropancreatic | 08/26 | 12/26 | | |
NCT05156203: Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | T-1301 Capsules | Taivex Therapeutics Corporation | Advanced Solid Tumor, Lymphoma | 01/27 | 12/27 | | |
| Recruiting | 1 | 78 | Japan, RoW | Pimitespib, TAS-116, Imatinib, Sunitinib | Taiho Pharmaceutical Co., Ltd. | Gastrointestinal Stromal Tumors | 12/25 | 12/25 | | |
NCT04180072: Atezolizumab Plus Bevacizumab With HCC and HBV Infection |
|
|
| Active, not recruiting | N/A | 51 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Carcinoma, Hepatocellular | 12/25 | 12/25 | | |
NCT05036486: The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer |
|
|
| Recruiting | N/A | 400 | RoW | next-generation sequencing | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital, Chang Gung Medical Foundation (Linkou Branch), Taipei Medical University Shuang Ho Hospital, Koo Foundation Sun Yat-Sen Cancer Center, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Chiayi, Taoyuan General Hospital, Ministry of Health and Welfare, Mackay Memorial Hospital | Biliary Tract Cancer (BTC) | 12/30 | 12/30 | | |
| Liu, Chen-Hua |
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients |
|
|
| Recruiting | 2 | 148 | RoW | JKB-122, Placebo | Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd | Chronic Hepatitis C | 08/16 | | | |
NCT05092074: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection |
|
|
| Recruiting | N/A | 100 | RoW | Vosevi 400/100/100 Oral Tablet | National Taiwan University Hospital | Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment, Effect of Drug | 12/22 | 02/23 | | |
| Recruiting | N/A | 350 | RoW | | National Taiwan University Hospital | Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Hemodialysis Complication | 02/24 | 03/24 | | |
NCT04768517: HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy |
|
|
| Recruiting | N/A | 300 | RoW | | National Taiwan University Hospital | Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus (HIV) Coinfection | 02/24 | 03/24 | | |
| Sticherling, Michael |
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis |
|
|
| Completed | 1 | 24 | Europe, US | CDX-0159, barzolvolimab, Normal saline | Celldex Therapeutics | Prurigo Nodularis | 07/23 | 07/23 | | |
|
| Sheu, Wayne H |
NCT01198730: Screen of DM by OGTT in Subjects Receiving CAG or MDCT for CAD |
|
|
| Recruiting | N/A | 2000 | RoW | | Taichung Veterans General Hospital | Diabetes Mellitus, Coronary Artery Disease | 12/20 | 12/24 | | |
NCT02886949: The Association Between Autoimmune or Inflammation and Thyroid Disease |
|
|
| Recruiting | N/A | 500 | RoW | | Taichung Veterans General Hospital | THYROTOXICOSIS | 12/20 | 12/24 | | |
NCT06271200: Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET) |
|
|
| Recruiting | N/A | 120 | RoW | Intermittent fasting and 10,000 steps per day | National Health Research Institutes, Taiwan, Tri-Service General Hospital, Chang Gung Memorial Hospital, National Taiwan University Hospital Hsin-Chu Branch, Taichung Armed Forces General Hospital | Metabolic Syndrome | 01/26 | 12/27 | | |
NCT06111833: Optimized Diagnosis and Precision Medicine of MODY |
|
|
| Recruiting | N/A | 1500 | RoW | | Taichung Veterans General Hospital, National Health Research Institutes, Taiwan | Maturity-Onset Diabetes of the Young (MODY), Type 2 Diabetes, Diabetes Complications | 04/28 | 05/28 | | |
| Lee, I Te |
NCT02885922: The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 6000 | RoW | anti-diabetic drug, Glucose lowering | Taichung Veterans General Hospital | Hyperglycemia | 12/24 | 12/24 | | |
| Hsu, Ching-Sheng |
| Recruiting | N/A | 15000 | RoW | | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Dalin Tzu Chi General Hospital | Liver Diseases, Humans, Progression, Carcinogenesis, Fatty Liver Disease, Hepatitis C, Hepatitis B, Hepatocellular Carcinoma, Liver Cirrhoses, Treatment Outcome | 12/21 | 12/21 | | |
| Yang, Sheng-Shun |
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement |
|
|
| Recruiting | 2 | 120 | Europe, Japan, US, RoW | TAS-120, Futibatinib | Taiho Oncology, Inc. | Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement | 06/25 | 06/26 | | |
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy |
|
|
| Active, not recruiting | 2 | 184 | Europe, RoW | GSK3228836, Bepirovirsen, GSK3528869A, Control | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 02/26 | 02/26 | | |
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection |
|
|
| Terminated | 1/2 | 135 | Europe, RoW | ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 10/24 | 10/24 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
NCT05092074: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection |
|
|
| Recruiting | N/A | 100 | RoW | Vosevi 400/100/100 Oral Tablet | National Taiwan University Hospital | Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment, Effect of Drug | 12/22 | 02/23 | | |
| Recruiting | N/A | 350 | RoW | | National Taiwan University Hospital | Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Hemodialysis Complication | 02/24 | 03/24 | | |
NCT04768517: HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy |
|
|
| Recruiting | N/A | 300 | RoW | | National Taiwan University Hospital | Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus (HIV) Coinfection | 02/24 | 03/24 | | |
NCT06277037: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) |
|
|
| Recruiting | N/A | 50 | Europe, US, RoW | Non-interventional | Arbutus Biopharma Corporation | Long Term Follow-up | 08/29 | 10/29 | | |
NCT04180072: Atezolizumab Plus Bevacizumab With HCC and HBV Infection |
|
|
| Active, not recruiting | N/A | 51 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Carcinoma, Hepatocellular | 12/25 | 12/25 | | |
| Dai, Chia-Yen |
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients |
|
|
| Recruiting | 2 | 148 | RoW | JKB-122, Placebo | Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd | Chronic Hepatitis C | 08/16 | | | |
NCT04133259: Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients |
|
|
| Recruiting | 2 | 44 | RoW | Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, HLX10 for Injection, HLX10, Nucleoside/nucleotide analogues, Entecavir, Tenofovir disoproxil fumarate | Henlix, Inc | Hepatitis B, Chronic | 04/22 | 07/22 | | |
| Recruiting | N/A | 200 | RoW | Observation only | Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital, National Taiwan University Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital, China Medical University, China, Mackay Memorial Hospital, Taipei Veterans General Hospital, Taiwan, Changhua Christian Hospital, Pusan National University Hospital, Asan Medical Center, Korea University, Inje University, Korea University Guro Hospital, Kyungpook National University Hospital, Seoul National University Hospital, Severance Hospital, Samsung Medical Center, Seoul National University Bundang Hospital, Soon Chun Hyang University, Seoul St. Mary's Hospital, Gachon University Gil Medical Center, Dong-A University Hospital, Gangnam Severance Hospital | Liver Fibroses, HepatoCellular Carcinoma, Cryoglobulinemia, Metabolic Disease, Diabetes Mellitus | 09/22 | 09/22 | | |
NCT05494528: Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy |
|
|
| Recruiting | N/A | 90 | RoW | Ropeginterferon alfa-2b, P1101, Entecavir | National Taiwan University Hospital, PharmaEssentia | Chronic Hepatitis B Virus Infection | 12/23 | 12/24 | | |
NCT04180072: Atezolizumab Plus Bevacizumab With HCC and HBV Infection |
|
|
| Active, not recruiting | N/A | 51 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Carcinoma, Hepatocellular | 12/25 | 12/25 | | |
| Bascom, Rebecca |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
NCT05239793: Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects |
|
|
| Recruiting | 1 | 30 | US | NJOY e-cigarette | Milton S. Hershey Medical Center, National Heart, Lung, and Blood Institute (NHLBI) | Chronic Obstructive Pulmonary Disease | 11/25 | 11/25 | | |
NCT05599321: Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling |
|
|
| Recruiting | N/A | 166 | US | Virtual Navigation System | Penn State University, Milton S. Hershey Medical Center | Lung Cancer | 10/25 | 10/25 | | |
| Boom, LN |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Untch, Michael |
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label |
|
|
| Recruiting | 4 | 108 | Europe | Ontruzant, SB3, Chemotherapy, Pertuzumab | Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd. | Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer | 04/23 | 07/23 | | |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency ( |
|
|
| Active, not recruiting | 2 | 11 | Europe | Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza | Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC | Malignant Neoplasm of Breast, Breast Cancer | 01/25 | 02/26 | | |
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer |
|
|
| Recruiting | 2 | 220 | Europe | Giredestrant, Triptorelin, Anastrozole | ETOP IBCSG Partners Foundation, Hoffmann-La Roche | Breast Cancer | 06/26 | 06/26 | | |
| Chen, Yuh-Min |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation |
|
|
| Recruiting | 2 | 40 | US, RoW | ABN401 | Abion Inc | Advanced Solid Tumors | 04/25 | 08/25 | | |
| Active, not recruiting | 2 | 240 | Europe, US, RoW | CAB-AXL-ADC, BA3011, PD-1 inhibitor | BioAtla, Inc., BioAtla Inc. | Non-Small-Cell Lung Cancer | 08/25 | 08/25 | | |
| Active, not recruiting | 1/2 | 332 | Canada, Japan, US, RoW | BLU-451, Carboplatin, Pemetrexed | Blueprint Medicines Corporation | Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q | 07/24 | 07/26 | | |
| Wang, Chen |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
| Recruiting | 3 | 516 | RoW | Tirofiban, Tirofiban Hydrochloride and Sodium Chloride Injection, Aspirin tablet, Clopidogrel tablet | Peking Union Medical College Hospital, Pharmaron (Chengdu) Clinical Services Co., Ltd. | Branch Atheromatous Disease | 07/25 | 10/25 | | |
NCT05506176: A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1208 | RoW | SIM0417, Simnotrelvir, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 01/23 | 03/23 | | |
NCT05761028: A Study of CM310 in Subjects With Moderate to Severe Asthma |
|
|
| Recruiting | 2/3 | 600 | RoW | CM310, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Moderate to Severe Asthma | 05/32 | 05/32 | | |
NCT05186909: A Study of CM310 in Subjects With Moderate to Severe Asthma |
|
|
| Completed | 2 | 52 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Asthma | 09/23 | 09/23 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT04664491: Effects of COPD Standardized Management on COPD Exacerbation |
|
|
| Not yet recruiting | N/A | 3456 | NA | Standardized COPD management, COPD management according to GOLD and China's guidelines for COPD care, Routine COPD management | China-Japan Friendship Hospital | Chronic Obstructive Pulmonary Disease | 09/22 | 12/22 | | |
NCT06231446: Extracorporeal Membrane Oxygenation for Respiratory Failure Patients |
|
|
| Recruiting | N/A | 400 | RoW | No intervention | China-Japan Friendship Hospital | Respiratory Failure Patients Treated With ECMO | 12/24 | 12/24 | | |
NCT03397355: Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy. |
|
|
| Recruiting | N/A | 1000 | RoW | | China-Japan Friendship Hospital | Lung Cancer | 12/22 | 12/22 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NCT06456749: Xishui Project for IDM of COPD and Comorbidities |
|
|
| Not yet recruiting | N/A | 4000 | NA | Integrated Disease Management | China-Japan Friendship Hospital, Peking Union Medical College, Heidelberg University | Chronic Obstructive Pulmonary Disease, Comorbidities and Coexisting Conditions | 10/25 | 03/26 | | |
NCT06573580: Primary Health Management for Chronic Obstructive Pulmonary Disease |
|
|
| Active, not recruiting | N/A | 6000 | RoW | The essential public health service（EPHS）for COPD | China-Japan Friendship Hospital | Pulmonary Disease, Chronic Obstructive Pulmonary Disease | 07/25 | 08/25 | | |
NM-in-RCIP, NCT04958447: Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China |
|
|
| Recruiting | N/A | 1000 | RoW | | China-Japan Friendship Hospital, Longyan First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Peking University International Hospital, Peking University People's Hospital, Peking University Shougang Hospital, Beijing Jingmei Group General Hospital, Beijing Fangshan District Liangxiang Hospital, Beijing Hospital, Beijing Coal Group General Hospital, Beijing Rehabilitation Hospital, Capital Medical University, Beijing 302 Hospital, Cangzhou People's Hospital, Cangzhou Central Hospital, Affiliated Hospital of Chengde Medical University, Huan'an First People's Hospital, The First Affiliated Hospital of Hebei North University, Hebei Sheng Xiong Ke Yi Yuan, The Second Hospital of Hebei Medical University, Affiliated Hospital of North China University of Science and Technology, First Hospital of Shijiazhuang City, Tangshan Central Hospital, Zhuozhou Hospital, Second Hospital of Jilin University, The First Hospital of Jilin University, The General Hospital of Northern Theater Command, The Affiliated Zhongshan Hospital of Dalian University, Dalian Municipal Central Hospital, The First Affiliated Hospital of Dalian Medical University, Affiliated Central Hospital of Shenyang Medical College, The Fourth Affiliated Hospital of China Medical University, First Hospital of China Medical University, General Hospital of Tianjin Medical University, Tianjin Chest Hospital, Tianjin Medical University Second Hospital, Special Medical Center of the Armed Police Force, The Second People Hospital of Wuhu, The First Affiliated Hospital of Anhui Medical University, Meizhou People's Hospital, The General Hospital of Southern Theater Command, First Affiliated Hospital, Sun Yat-Sen University, Hainan People's Hospital, The First Affiliated Hospital of Zhengzhou University, The General Hospital of Eastern Theater Command, Huai an First People Hospital, Subei People's Hospital of Jiangsu Province, The First People's Hospital of Lianyungang, Nanjing No.1 Hospital, The Affiliated Jiangning Hospital of Nanjing Medical University, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Soochow University, Suzhou Municipal Hospital, Suzhou Hospital of Traditional Chinese Medicine, Jiangxi Provincial People's Hopital, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Shaanxi Provincial People's Hospital, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Xi an Medical University, Xijing Hospital, Sichuan Provincial People's Hospital, No.2 People Hospital of Fuyang City, The Second Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Tongji Hospital, Jingzhou Central Hospital, Wuhan University, Wuhan Central Hospital, Central Command General Hospital, Second Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, Heze Municipal Hospital, Qingdao Central Hospital, Taian City Central Hospital, Yantai Yuhuangding Hospital, Zibo First Hospital, Huashan Hospital, Fudan University, Ruijin Hospital, Dongfang Hospital Affiliated to Tongji University, Changhai Hospital, Henan Provincial People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Taikang Xianlin Drum Tower Hospital, Xinqiao Hospital of Chongqing, The First People Hospital of Nantong City, Wuxi People's Hospital, The First People's Hospital of Changzhou, The First People's Hospital of Yunnan, People Hospital of Dali Bai Autonomous Prefecture, The First Affiliated Hospital of Kunming Medical College, The Second Affiliated Hospital of Air Force Military Medical University, The 306 Hospital of People's Liberation Army, The Sixth Central Hospital of PLA, Peking University Third Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, China Rehabilitation Research Center, The Third People Hospital of Datong, Dezhou People's Hospital | Nutritional Deficiency | 07/21 | 08/21 | | |
| Not yet recruiting | N/A | 5000 | NA | | China-Japan Friendship Hospital | COPD | 05/22 | 05/30 | | |
NCT05032898: Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II |
|
|
| Not yet recruiting | N/A | 1500 | NA | | China-Japan Friendship Hospital | Pulmonary Disease, Chronic Obstructive | 12/22 | 12/23 | | |
| Recruiting | N/A | 400 | RoW | | China-Japan Friendship Hospital, Chinese Academy of Medical Sciences, Second Affiliated Hospital, School of Medicine, Zhejiang University, Capital Medical University, Peking University Third Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Obstructive Pulmonary Disease | 01/25 | 12/25 | | |
| Vidal, Oscar Juan |
| Active, not recruiting | 3 | 511 | Europe, US, RoW | HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI) | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Limited-Stage Small Cell Lung Cancer | 07/25 | 12/26 | | |
USZ-STRIKE, NCT05522660: Immunotherapy or Targeted Therapy with or Without Stereotactic Radiosurgery for Patients with Brain Metastases from Melanoma or Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 190 | Europe | Stereotactic radiosurgery, Immune checkpoint inhibitor, standard of care treatment | ETOP IBCSG Partners Foundation, USZ Foundation | Non-Small Cell Lung Cancer, Melanoma | 01/26 | 12/26 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 186 | Europe, Canada, US, RoW | inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta | iTeos Therapeutics, iTeos Belgium SA | Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer | 04/25 | 05/25 | | |
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC |
|
|
| Withdrawn | 2 | 47 | Europe | Sotorasib, Lenvatinib | ETOP IBCSG Partners Foundation, Amgen, Eisai Inc. | Metastatic Non Small Cell Lung Cancer, KRAS G12C | 09/26 | 12/26 | | |
GALLANT-1, NCT05240131 / 2021-003189-11: A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). |
|
|
| Active, not recruiting | 1/2 | 88 | Europe | GB1211, Placebo, Atezolizumab | Galecto Biotech AB, Linical Europe GmbH, Hoffmann-La Roche | Non-Small Cell Lung Cancer | 05/24 | 11/25 | | |
| Terminated | 1/2 | 52 | Europe, US, RoW | NM21-1480 | Numab Therapeutics AG | Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer | 02/24 | 02/24 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
|
|
| Recruiting | 1 | 475 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | GlaxoSmithKline | Neoplasms | 08/25 | 02/27 | | |
NCT03850067: A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | 90 | Europe | CC-90011, Cisplatin, Carboplatin, Etoposide, Nivolumab | Celgene | Small Cell Lung Carcinoma | 07/24 | 07/24 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion |
|
|
| Completed | N/A | 76 | Europe | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 09/23 | 09/23 | | |
| Wu, Chieh-Liang |
NCT04875260: Taiwan Center of Outcome and Resource Evaluation |
|
|
| Recruiting | N/A | 600000 | RoW | Critical Care | National Taiwan University Hospital | Critical Illness | 07/40 | 12/40 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
